FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012816102> ?p ?o ?g. }

• W2012816102 endingPage "266" @default.
• W2012816102 startingPage "265" @default.
• W2012816102 abstract "A recent study demonstrated a greater propensity for HIV-1 subtype C to develop a K65R mutation under in-vitro selection with tenofovir compared with subtype B or other non-B subtypes [1]. The mechanistic basis for this in-vitro observation was not clear because the single nucleotide change is identical for the K65R substitution in either subtype B or subtype C. For subtype B, a switch from AAA to AGA occurs. For subtype C, a switch from AAG to AGG occurs. The third codon position, however, is different for subtype C, reflecting redundancy in the genetic code for lysine and a natural variation among different HIV-1 subtypes. The authors speculate that this third codon position difference or other genetic changes may influence the propensity for the development of K65R in subtype C HIV-1. We evaluated patients with subtype C, subtype B, and other non-B HIV-1 subtypes for virological failure and the development of resistance in two phase III clinical trials of tenofovir disoproxil fumarate (DF). These studies enrolled patients primarily from the United States, Europe and South America. Within these studies, approximately 7% of the 1200 patients enrolled were infected with non-B HIV-1 subtypes. Study 903 assessed the combination of tenofovir DF with lamivudine and efavirenz, and study 934 assessed the combination of tenofovir DF with emtricitabine and efavirenz. Although neither study was statistically powered to address efficacy in patients with non-B subtypes, the virological failure rates were similar between patients with subtype B or non-B HIV-1 subtypes (15.5 versus 19%, respectively, P = 0.75 for study 903 at week 144; 19 versus 13%, respectively, P = 1.0 for study 934 at week 48) [2,3]. Moreover, among the 10 patients with subtype C HIV-1 treated with tenofovir DF in both studies, only one patient was classified as a virological failure, and this patient did not develop a K65R mutation or any other resistance mutations. One patient developed K65R with a non-B subtype, a subtype AG patient from study 903. This patient did not show the AAG polymorphism at codon 65, but rather the AAA K65 codon typically found among subtype B patients. In summary, in highly suppressive antiretroviral regimens that include tenofovir DF, efavirenz and either emtricitabine or lamivudine, there was no evidence of a higher rate of virological failure or the development of K65R among patients with non-B HIV-1 subtypes or in particular among patients with subtype C HIV-1. The studies were limited by the number of patients enrolled with non-B subtypes. A larger study of tenofovir DF with zidovudine and lamivudine in African patients infected with subtypes A, C and D, however, concluded similarly that patients with subtypes A, C and D respond effectively to that drug combination with a low incidence of the development of K65R (three out of 20 virological failures; 15%) [4]. Another study [5], conducted exclusively among subtype C-infected patients in Botswana, demonstrated a higher rate of K65R development among patients treated with didanosine, stavudine, and efavirenz (seven out of 23 virological failures; 30%). The rate of thymidine analogue mutation development was also high in that trial, with eight out of 13 (62%) virological failure patients who were taking combivir developing thymidine analogue mutations, suggesting an overall higher rate of resistance development in that study. Overall, additional studies with the prospective enrollment of patients with subtype C and other comparator HIV-1 subtypes will be necessary to rule out any differential propensity for the development of K65R among subtype C patients in the clinical setting. Currently available clinical data, however, do not suggest a higher rate of K65R development among patients with subtype C." @default.
• W2012816102 created "2016-06-24" @default.
• W2012816102 creator A5001632717 @default.
• W2012816102 creator A5008851778 @default.
• W2012816102 creator A5033625804 @default.
• W2012816102 creator A5051466983 @default.
• W2012816102 date "2007-01-11" @default.
• W2012816102 modified "2023-09-26" @default.
• W2012816102 title "K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials" @default.
• W2012816102 cites W1995559092 @default.
• W2012816102 cites W2021660989 @default.
• W2012816102 cites W83241575 @default.
• W2012816102 doi "https://doi.org/10.1097/qad.0b013e32801199ee" @default.
• W2012816102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17197831" @default.
• W2012816102 hasPublicationYear "2007" @default.
• W2012816102 type Work @default.
• W2012816102 sameAs 2012816102 @default.
• W2012816102 citedByCount "31" @default.
• W2012816102 countsByYear W20128161022012 @default.
• W2012816102 countsByYear W20128161022013 @default.
• W2012816102 countsByYear W20128161022019 @default.
• W2012816102 crossrefType "journal-article" @default.
• W2012816102 hasAuthorship W2012816102A5001632717 @default.
• W2012816102 hasAuthorship W2012816102A5008851778 @default.
• W2012816102 hasAuthorship W2012816102A5033625804 @default.
• W2012816102 hasAuthorship W2012816102A5051466983 @default.
• W2012816102 hasConcept C104317684 @default.
• W2012816102 hasConcept C126322002 @default.
• W2012816102 hasConcept C135763542 @default.
• W2012816102 hasConcept C142462285 @default.
• W2012816102 hasConcept C156719811 @default.
• W2012816102 hasConcept C159047783 @default.
• W2012816102 hasConcept C182707283 @default.
• W2012816102 hasConcept C2522874641 @default.
• W2012816102 hasConcept C2777869810 @default.
• W2012816102 hasConcept C2779344132 @default.
• W2012816102 hasConcept C2779778239 @default.
• W2012816102 hasConcept C2780593183 @default.
• W2012816102 hasConcept C2781432083 @default.
• W2012816102 hasConcept C2993143319 @default.
• W2012816102 hasConcept C3013748606 @default.
• W2012816102 hasConcept C54355233 @default.
• W2012816102 hasConcept C67705224 @default.
• W2012816102 hasConcept C71924100 @default.
• W2012816102 hasConcept C86803240 @default.
• W2012816102 hasConceptScore W2012816102C104317684 @default.
• W2012816102 hasConceptScore W2012816102C126322002 @default.
• W2012816102 hasConceptScore W2012816102C135763542 @default.
• W2012816102 hasConceptScore W2012816102C142462285 @default.
• W2012816102 hasConceptScore W2012816102C156719811 @default.
• W2012816102 hasConceptScore W2012816102C159047783 @default.
• W2012816102 hasConceptScore W2012816102C182707283 @default.
• W2012816102 hasConceptScore W2012816102C2522874641 @default.
• W2012816102 hasConceptScore W2012816102C2777869810 @default.
• W2012816102 hasConceptScore W2012816102C2779344132 @default.
• W2012816102 hasConceptScore W2012816102C2779778239 @default.
• W2012816102 hasConceptScore W2012816102C2780593183 @default.
• W2012816102 hasConceptScore W2012816102C2781432083 @default.
• W2012816102 hasConceptScore W2012816102C2993143319 @default.
• W2012816102 hasConceptScore W2012816102C3013748606 @default.
• W2012816102 hasConceptScore W2012816102C54355233 @default.
• W2012816102 hasConceptScore W2012816102C67705224 @default.
• W2012816102 hasConceptScore W2012816102C71924100 @default.
• W2012816102 hasConceptScore W2012816102C86803240 @default.
• W2012816102 hasIssue "2" @default.
• W2012816102 hasLocation W20128161021 @default.
• W2012816102 hasLocation W20128161022 @default.
• W2012816102 hasOpenAccess W2012816102 @default.
• W2012816102 hasPrimaryLocation W20128161021 @default.
• W2012816102 hasRelatedWork W1978280188 @default.
• W2012816102 hasRelatedWork W1997982838 @default.
• W2012816102 hasRelatedWork W2045367162 @default.
• W2012816102 hasRelatedWork W2141680152 @default.
• W2012816102 hasRelatedWork W2323941313 @default.
• W2012816102 hasRelatedWork W2752427976 @default.
• W2012816102 hasRelatedWork W2766522384 @default.
• W2012816102 hasRelatedWork W2883869563 @default.
• W2012816102 hasRelatedWork W2884449129 @default.
• W2012816102 hasRelatedWork W3136426020 @default.
• W2012816102 hasVolume "21" @default.
• W2012816102 isParatext "false" @default.
• W2012816102 isRetracted "false" @default.
• W2012816102 magId "2012816102" @default.
• W2012816102 workType "article" @default.